TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7644924

Group type: EXPERIMENTAL
Intervention: Paclitaxel (135-225 mg/m2) and Carboplatin (250-400 mg/m2)
Number of subjects: 29
Study: 2654758

Group type: EXPERIMENTAL
Intervention: L-carnitine therapy (2 g twice daily for 45 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 321198

Group type: EXPERIMENTAL
Intervention: Mesoridazine (10 mg tablets)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30497312

Group type: COMPARATOR
Intervention: Traditional acupuncture
Number of subjects: 17

Group type: COMPARATOR
Intervention: Eye acupuncture
Number of subjects: 17

Group type: COMPARATOR
Intervention: Wrist–ankle acupuncture
Number of subjects: 17

Group type: COMPARATOR
Intervention: Superficial acupuncture
Number of subjects: 17

Group type: COMPARATOR
Intervention: Moxibustion
Number of subjects: 17

Group type: COMPARATOR
Intervention: Electroacupuncture
Number of subjects: 17

Group type: COMPARATOR
Intervention: Ear acupuncture
Number of subjects: 17

Group type: COMPARATOR
Intervention: Abdominal acupuncture
Number of subjects: 17
Study: 29577365

Group type: EXPERIMENTAL
Intervention: 20 mg oleuropein
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 26758035

Group type: EXPERIMENTAL
Intervention: Craniosacral therapy (IG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard care (CG)
Number of subjects: 30
Study: 24967345

Group type: EXPERIMENTAL
Intervention: NeReBot robotic therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional rehabilitation therapy
Number of subjects: 0
Study: 22397784

Group type: EXPERIMENTAL
Intervention: Tadalafil (10 mg nightly) with standard treatment of BPH
Number of subjects: 132

Group type: COMPARATOR
Intervention: Standard treatment of BPH (placebo group)
Number of subjects: 132
Study: 20849433

Group type: EXPERIMENTAL
Intervention: Ultrasonic mechanical instrumentation (UMI) with home-care use of amine fluoride/stannous fluoride (AmF/SnF(2)) mouthrinse and toothpaste
Number of subjects: 38
Study: 18063874

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (L-AmB) prophylaxis
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control (no antifungal prophylaxis)
Number of subjects: 99
Study: 15240596

Group type: EXPERIMENTAL
Intervention: Individualized dosing regimen (ID) starting at 0.2 mg/d, increased by 0.2 mg/d increments to a maximum of 0.8 mg/d
Number of subjects: 387

Group type: COMPARATOR
Intervention: Fixed body weight-based dosing regimen (FD) with sequential doses of 4, 8, and 12 microg/kg.d GH
Number of subjects: 387
Study: 11268982

Group type: EXPERIMENTAL
Intervention: Distal pancreatectomy plus end-to-side pancreaticojejunostomy (group A)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Pancreaticoduodenectomy (group B)
Number of subjects: 18
Study: 9564065

Group type: EXPERIMENTAL
Intervention: Removal of dermoid cysts with an endobag
Number of subjects: 55

Group type: COMPARATOR
Intervention: Removal of dermoid cysts without an endobag
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Infertile women (20 total)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 55
Study: 7987360

Group type: EXPERIMENTAL
Intervention: alpha-tocopherol supplementation
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study: 2657202

Group type: EXPERIMENTAL
Intervention: Kelman‐Multiflex lenses
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Dubroff lenses
Number of subjects: 92
Study: 8317646

Group type: EXPERIMENTAL
Intervention: 10% lignocaine gel with absorption promoter
Number of subjects: 34

Group type: COMPARATOR
Intervention: EMLA cream
Number of subjects: 34
Study: 357073

Group type: EXPERIMENTAL
Intervention: 5 consecutive topical applications with APF gel (1.2% F, pH 3.2)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: 10 consecutive topical applications with APF gel (1.2% F, pH 3.2)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: 25 consecutive topical applications with APF gel (1.2% F, pH 3.2)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Untreated control groups
Number of subjects: 600
Study: 31849093

Group type: EXPERIMENTAL
Intervention: High-Caloric Fatty Diet (HCFD) - 405 kcal/day, 100% fat
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: HCFD
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: HCFD (post hoc analysis)
Number of subjects: 201
Study: 30668660

Group type: EXPERIMENTAL
Intervention: Buccal miniscrews
Number of subjects: 80

Group type: COMPARATOR
Intervention: Molar blocks
Number of subjects: 80
Study: 28122851

Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hemodiafiltration (HDF)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (none)
Number of subjects: 12
Study: 27541067

Group type: EXPERIMENTAL
Intervention: Auricular acupressure therapy applied on acupoints (Jagung, Sinmun, Gyogam, Naebunbi) for 3 days during periods of extreme primary dysmenorrhea.
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo control group with skin paper tape without acupressure needle applied on the same acupoints.
Number of subjects: 91
Study: 24656425

Group type: EXPERIMENTAL
Intervention: Artemether (80 mg once per day during the second week and fourth week)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (identical looking capsules)
Number of subjects: 100
Study: 23272206

Group type: EXPERIMENTAL
Intervention: Text-message reminders
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Text-message reminders under study conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Text-message reminders implemented by the Ministry of Health
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Text-message reminders scaled up nationally
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Text-message reminders with a 5% effect size
Number of subjects: 0
Study: 19440077

Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (36, 54, 72, 90, or 108 mg/d)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: OROS methylphenidate
Number of subjects: 226
Study: 17264729

Group type: EXPERIMENTAL
Intervention: 50 microg neosaxitoxin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 15161378

Group type: EXPERIMENTAL
Intervention: Visually influenced (McGurk) responses when the auditory signal was a nonword and formed a word (Experiment 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Slow responses (Experiment 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stimuli matched on physical properties (Experiment 3)
Number of subjects: 0
Study: 11642642

Group type: EXPERIMENTAL
Intervention: Combined spa-exercise therapy (3 weeks duration) including group physical exercises, walking, correction therapy, hydrotherapy, sports, and sauna visits.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (usual drug treatment and weekly group physical therapy).
Number of subjects: 120
Study: 9697742

Group type: EXPERIMENTAL
Intervention: Imiquimod treatment
Number of subjects: 0
Study: 8015082

Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2492232

Group type: EXPERIMENTAL
Intervention: Depot leuprolide acetate (LA) 3.75 mg IM every 4 weeks for 24 weeks (Group A)
Number of subjects: 38

Group type: COMPARATOR
Intervention: IM placebo with the same injection schedule (Group B)
Number of subjects: 38
Study: 4338548

Group type: EXPERIMENTAL
Intervention: Simultaneous alpha and beta receptor blockade
Number of subjects: 5
Study: 30278943

Group type: EXPERIMENTAL
Intervention: Fluorescence imaging (FI) using indocyanine green
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (no fluorescence imaging)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Fluorescence imaging (FI)
Number of subjects: 110
Study: 27181910

Group type: EXPERIMENTAL
Intervention: Teneligliptin 5 to 40 mg once daily for 24 weeks
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Teneligliptin 20 mg once daily during 28-week open label extension
Number of subjects: 447

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 447
Study: 24838155

Group type: EXPERIMENTAL
Intervention: Liraglutide (1.2 mg/day)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Saxagliptin (5 mg once daily)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Vildagliptin (50 mg twice daily)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 178
Study: 22584293

Group type: EXPERIMENTAL
Intervention: Plastic ring drape
Number of subjects: 199

Group type: COMPARATOR
Intervention: Standard cloth towels (control)
Number of subjects: 199
Study: 20144258

Group type: EXPERIMENTAL
Intervention: Rooibos tea (400 ml)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Green tea (400 ml)
Number of subjects: 17
Study: 18396251

Group type: EXPERIMENTAL
Intervention: Acupuncture (unilateral manual stimulation of acupuncture points LU7 and KD6)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no acupuncture)
Number of subjects: 60
Study: 16288142

Group type: EXPERIMENTAL
Intervention: Marital‐relationship enhancement program (MREP) based on Gottman's 'sound marital house' theory
Number of subjects: 71

Group type: COMPARATOR
Intervention: No treatment (Control group)
Number of subjects: 71
Study: 12705519

Group type: EXPERIMENTAL
Intervention: Experimental group (n=7)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (n=6)
Number of subjects: 13
Study: 10806051

Group type: EXPERIMENTAL
Intervention: Etodolac (300 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 8841291

Group type: EXPERIMENTAL
Intervention: Refractive keratotomy using the Casebeer system
Number of subjects: 324
Study: 1732429

Group type: EXPERIMENTAL
Intervention: Bolus injection of high-dose recombinant interleukin-2 (rIL-2) three times daily
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Continuous infusion of high-dose recombinant interleukin-2 (rIL-2) 24-hour infusion
Number of subjects: 94
Study: 6396239

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide-amiloride combination
Number of subjects: 45
Study: 30964238

Group type: EXPERIMENTAL
Intervention: Guava toner with 6% guava extract
Number of subjects: 21

Group type: COMPARATOR
Intervention: Base toner (control)
Number of subjects: 21
Study: 29024599

Group type: EXPERIMENTAL
Intervention: Circuit training with probiotics (CTP)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Circuit training (CT)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Probiotics (P)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Circuit training with placebo (CT)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sedentary placebo control
Number of subjects: 48
Study: 27433807

Group type: EXPERIMENTAL
Intervention: Anodal stimulation of left DLPFC
Number of subjects: 42

Group type: COMPARATOR
Intervention: Cathodal stimulation of left DLPFC
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham stimulation of left DLPFC
Number of subjects: 42
Study: 24910546

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 231

Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 231
Study: 22864336

Group type: EXPERIMENTAL
Intervention: External beam radiotherapy (ERT) plus vaginal brachytherapy (VBT)
Number of subjects: 527

Group type: COMPARATOR
Intervention: Vaginal irradiation alone (VBT)
Number of subjects: 527
Study: 20557927

Group type: EXPERIMENTAL
Intervention: Nurse-monitored ART care
Number of subjects: 812

Group type: COMPARATOR
Intervention: Doctor-monitored ART care
Number of subjects: 812
Study: 18608310

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for GAD
Number of subjects: 29
Study: 16108073

Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portal-systemic shunting (TIPS)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Repeated large volume paracentesis (LVP)
Number of subjects: 109
Study: 12001821

Group type: EXPERIMENTAL
Intervention: Tolterodine 5 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Oxybutynin 5 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Oxybutynin 2.5 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Oxybutynin 7.5 mg
Number of subjects: 16
Study: 10726106

Group type: EXPERIMENTAL
Intervention: 3-week hypocaloric diet (3.9 MJ (941 kcal))
Number of subjects: 15
Study: 7795832

Group type: EXPERIMENTAL
Intervention: Weight loss alone
Number of subjects: 2382

Group type: EXPERIMENTAL
Intervention: Restricted sodium intake alone
Number of subjects: 2382

Group type: EXPERIMENTAL
Intervention: Combination of weight loss and sodium restriction
Number of subjects: 2382

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2382
Study: 1953227

Group type: EXPERIMENTAL
Intervention: Topical 0.075% capsaicin cream
Number of subjects: 252

Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 252
Study: 6969867

Group type: EXPERIMENTAL
Intervention: Chronic cerebellar stimulation
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (functional or placebo stimulation)
Number of subjects: 8
Study: 31498308

Group type: EXPERIMENTAL
Intervention: Prescribed pulmonary exercise group (PG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-exercise control group (CG)
Number of subjects: 0
Study: 27815861

Group type: EXPERIMENTAL
Intervention: Moderate intensity physical activity
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Sedentary activity
Number of subjects: 52
Study: 26529311

Group type: EXPERIMENTAL
Intervention: Quality assurance plan implemented across clinical centers and central reading units
Number of subjects: 0
Study: 24577921

Group type: EXPERIMENTAL
Intervention: Ocucure (Test drug) 500mg, two tablets twice daily for 6-8 weeks
Number of subjects: 111

Group type: COMPARATOR
Intervention: Leutivit (Control drug) 250mg, two tablets twice daily for 6-8 weeks
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Ocucure (Test drug)
Number of subjects: 111
Study: 21183110

Group type: EXPERIMENTAL
Intervention: Standard corneal collagen crosslinking (CXL)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham control (riboflavin alone)
Number of subjects: 15
Study: 20025421

Group type: EXPERIMENTAL
Intervention: Human figure drawings (HFDs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Verbal condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both HFD and verbal conditions
Number of subjects: 0
Study: 17183019

Group type: EXPERIMENTAL
Intervention: Improved stoves (planchas)
Number of subjects: 504

Group type: COMPARATOR
Intervention: Traditional open fires
Number of subjects: 504
Study: 14749712

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 6500

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 6500
Study: 12564317

Group type: EXPERIMENTAL
Intervention: Heidelberg Retina Tomograph II
Number of subjects: 20
Study: 9695216

Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide (1.5-2.0 mg/kg/day for 6 months)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Intravenous cyclophosphamide pulses (20 mg/kg/monthly for at least 6 pulses) combined with oral prednisolone (40-60 mg/day for 1.5 months with tapering)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide
Number of subjects: 31

Group type: COMPARATOR
Intervention: Intravenous cyclophosphamide pulses
Number of subjects: 31
Study: 9846242

Group type: EXPERIMENTAL
Intervention: Physical activity profiles of adults with mild and moderate learning disabilities
Number of subjects: 24

Group type: COMPARATOR
Intervention: Comparison with the general population
Number of subjects: 24

Group type: COMPARATOR
Intervention: Department of Health recommendations for physical activity
Number of subjects: 24
Study: 1864449

Group type: EXPERIMENTAL
Intervention: 4% indomethacin spray
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 6347110

Group type: EXPERIMENTAL
Intervention: Nebulized 0.5% fenoterol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nebulized 1% isoetharine hydrochloride
Number of subjects: 40
Study: 31343103

Group type: EXPERIMENTAL
Intervention: Implantable loop recorder (ILR) - 'Reveal XT', monitoring duration up to 3 months
Number of subjects: 32

Group type: COMPARATOR
Intervention: Noninvasive ambulatory ECG monitoring (NIAM) - 'Spyder' device, monitoring duration up to 14 days
Number of subjects: 32
Study: 31342534

Group type: EXPERIMENTAL
Intervention: ondansetron
Number of subjects: 125
Study: 28292641

Group type: EXPERIMENTAL
Intervention: Lanreotide (LAN) 120mg every 28 days until disease progression or unacceptable toxicity
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Lanreotide (LAN)
Number of subjects: 222
Study: 26915677

Group type: EXPERIMENTAL
Intervention: Idelalisib (100 mg twice daily)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 24994555

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 279

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 279
Study: 23232637

Group type: EXPERIMENTAL
Intervention: Endoscopic sphincterotomy (ES)
Number of subjects: 82

Group type: COMPARATOR
Intervention: No endoscopic sphincterotomy (non-ES)
Number of subjects: 82
Study: 19716238

Group type: EXPERIMENTAL
Intervention: EG 2: 70-85% HR max, n=20
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: EG 1: 50-65% HR max, n=18
Number of subjects: 60

Group type: COMPARATOR
Intervention: CG: no intervention, n=21
Number of subjects: 60
Study: 17398147

Group type: EXPERIMENTAL
Intervention: Nonmedicated PD patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medicated PD patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy elderly controls
Number of subjects: 0
Study: 15863638

Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure treatment
Number of subjects: 36

Group type: COMPARATOR
Intervention: CD8+ T-lymphocytes of OSA patients
Number of subjects: 36
Study: 12038931

Group type: EXPERIMENTAL
Intervention: Reading on paper in their mother tongue
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Reading on screen in their mother tongue
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Reading on paper in English
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Reading on screen in English
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Reading in their mother tongue (combined paper and screen)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Reading on paper vs screen
Number of subjects: 114
Study: 9296408

Group type: EXPERIMENTAL
Intervention: Midazolam (30 microg/kg)
Number of subjects: 60
Study: 8362947

Group type: EXPERIMENTAL
Intervention: Preterm birth prevention program (intervention group)
Number of subjects: 2395

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2395
Study: 30156211

Group type: EXPERIMENTAL
Intervention: Periarticular multimodal drug injection (200 mg ropivacaine, 30 mg ketorolac tromethamine, 0.3 mg epinephrine, 5 mg hexadecadrol)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Periarticular multimodal drug injection
Number of subjects: 110

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 110
Study: 26857465

Group type: COMPARATOR
Intervention: Unassisted TPB
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Effortful swallow
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Finger-resisted TPB
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Device-resisted TPB
Number of subjects: 13

Group type: COMPARATOR
Intervention: Saliva swallow
Number of subjects: 13

Group type: COMPARATOR
Intervention: 15 mL water swallow
Number of subjects: 13
Study: 25381136

Group type: EXPERIMENTAL
Intervention: Eribulin (1.4 mg/m2 on days 1 and 8 every 21 days)
Number of subjects: 1864

Group type: COMPARATOR
Intervention: Control (treatment of physician’s choice or capecitabine 1.25 g/m2 b.i.d. on days 1–14 every 21 days)
Number of subjects: 1864

Group type: EXPERIMENTAL
Intervention: Eribulin
Number of subjects: 1864
Study: 21769734

Group type: EXPERIMENTAL
Intervention: High-intensity endurance training (4 days a week for 12 weeks at 75-80% maximum oxygen consumption for 45 min)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: High-intensity endurance training
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 16
Study: 20571291

Group type: EXPERIMENTAL
Intervention: Tigecycline
Number of subjects: 0
Study: 18322990

Group type: EXPERIMENTAL
Intervention: Tuberculin skin test (TST) with 10 mm cutoff
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Tuberculin skin test (TST) with 5 mm cutoff
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Second-step TST
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: QuantiFeron test (QIFN)
Number of subjects: 61
Study: 15964114

Group type: EXPERIMENTAL
Intervention: Isokinetic dynamometer assessment at various velocities (10 to 300 degrees/s)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Normalized passive resistance measurement
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Reflex responses elicitation
Number of subjects: 27
Study: 14657750

Group type: EXPERIMENTAL
Intervention: Transpedicular microscopic discectomy and transverse process resection (Group C)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Transverse process resection (Group B)
Number of subjects: 12

Group type: COMPARATOR
Intervention: No release (Group A)
Number of subjects: 12
Study: 10228288

Group type: EXPERIMENTAL
Intervention: Short course indomethacin (0.2 to 0.1 to 0.1 mg/kg in 24 hours, n = 31)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Long course indomethacin (0.1 mg/kg every 24 hours for 7 times, n = 30)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Short course indomethacin
Number of subjects: 61

Group type: COMPARATOR
Intervention: Long course indomethacin
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Short course indomethacin and Long course indomethacin
Number of subjects: 61